Johnson & Johnson Gets CDSCO Panel Okay To Study Anti-cancer Drug Lazertinib/Amivantamab

Published On 2022-11-04 12:30 GMT   |   Update On 2022-11-04 12:30 GMT
Advertisement

New Delhi: Pharmaceutical major Johnson and Johnson has got green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization ,(CDSCO) to conduct the Phase III clinical trial of the anti cancer drug Lazertinib/Amivantamab.

However this nod is subjected to the condition that study should be conducted initially in 25 subjects from India and applicant should submit their data for review by the committee for further continuation of the trial.
Furthermore, it is stated that death irrespective of its cause i.e. PD should be considered as Serious Adverse Event (SAE) and same to be reported to the CDSCO as per provisions of the New Drugs and Clinical Trial Rules, 2019 during the trial.
This came after the firm presented Phase III clinical trial protocol no. 61186372NSC3004 (PALOMA 3) before the committee.

Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). It is a brain-penetrant, irreversible EGFR-TKI that targets the T790M mutation and activating EGFR mutations Ex19del and L858R, while sparing wild type-EGFR.

Amivantamab is an epidermal growth factor (EGF) and mesenchymal–epithelial transition (MET) receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.

Amivantamab is a bispecific epidermal growth factor (EGF)receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

At the recent SEC meeting for Oncology and Hematology held on October 19th 2022, the expert panel reviewed the Phase III clinical trial protocol of anti cancer drug Lazertinib/Amivantamab Regime presented by Johnson and Johnson.
After detailed deliberation, the committee recommended the grant of permission to conduct the study with following conditions-
1.The study should be conducted initially in 25 subjects from India and applicant should submit their data for review by the committee for further continuation of the trial.
2. Death irrespective of its cause i.e. PD should be considered as SAE and same to be reported to the CDSCO as per provisions of the New Drugs and Clinical Trial Rules, 2019 during the trial.
Accordingly, the expert panel directed that the firm should submit protocol addendum for the same to CDSCO
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News